Navy to Grant Exclusive License to Adaptive Phage Therapeutics for Antibiotic Research

Summary

The US Department of the Navy has announced its intention to grant Adaptive Phage Therapeutics, Inc. a non-exclusive, worldwide license to utilize its patented inventions related to bacteriophage compositions and methods for combating antibiotic-resistant bacteria.